Compare Adaptive Biotechnologies Corp (ADPT) vs iShares Bitcoin Trust (IBIT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares Bitcoin Trust — how do they compare? Adaptive Biotechnologies Corp trades at $19.98 (market cap $3.33B), while iShares Bitcoin Trust trades at $35.11. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.
| ADPT | IBIT | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Crypto-linked |
52-Week High | $22.37 | $71.29 |
52-Week Low | $10.24 | $33.29 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
IBIT trades at $36.12, up 3.58% today, with a bullish technical signal despite bearish moving averages. Key support lies at $35 and resistance at $37. The stock faces headwinds from sector volatility and significant ETF outflows, as reported by Zacks Investment Research on 2026-07-06. Recent news highlights competitive pressures among Bitcoin ETFs, with IBIT leading in assets under management according to The Motley Fool on 2026-06-29.
The outlook remains cautious due to market sentiment shifts and regulatory uncertainties. Investment opportunities hinge on the company's ability to maintain its asset scale advantage, while risks include continued investor outflows and broader crypto market declines impacting related equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →
